|
|
Cat. No. 188 002 |
200 µl antiserum, lyophilized. For reconstitution add 200 µl H2O, then aliquot and store at -20°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
Applications | |
Immunogen | Recombinant protein corresponding to residues near the amino terminus of human MAP2 (UniProt Id: P11137-4) |
Reactivity |
Reacts with: human (P11137), rat (P15146), mouse (P20357), chicken. Other species not tested yet. |
Specificity | Specific for MAP2; recognizes all four isoforms. |
Matching control protein/peptide | 188-0P |
Remarks |
WB: Due to the large size of this protein, we recommend NuPAGE 3-8% Tris-Acetate gels for SDS-PAGE. |
Data sheet | 188_002.pdf |
|
There are two major classes of heat-stable microtubule-associated proteins (MAPs): MAP2 and tau (MAPT). Both bind microtubules and regulate their polymerization and stability—a critical process for maintaining cellular architecture and dynamics (1).
MAP2 exists in four main isoforms—MAP2A, MAP2B, MAP2C, and MAP2D—via alternative splicing. The high molecular weight isoforms MAP2A/B (~250 kDa) and lower molecular weight isoforms MAP2C/D (~70 kDa) all share a conserved microtubule-binding core domain, important for dendritic stabilization and neuritogenesis (2).
Since microtubule dynamics are central to cell division, migration, and morphology, aberrations in MAP2 and tau expression have been implicated in several types of cancer.
Consequently, MAP2 expression has diagnostic and prognostic relevance in neuro-oncology. MAP2 immunoreactivity helps distinguish glial neoplasms in neuropathology, and its expression tends to vary according to tumor grade (3). While classic low-grade gliomas often show robust MAP2 staining, higher-grade tumors may exhibit less-specific and more heterogeneous patterns. Moreover, in melanoma, reduced MAP2 expression correlates with increased tumor aggressiveness, underscoring its potential role as a tumor suppressive marker (4).